Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.
Caballero I, Aira LE, Lavastida A, Popa X, Rivero J, González J, Mesa M, González N, Coba K, Lorenzo-Luaces P, Wilkinson B, Santiesteban Y, Santiesteban Y, Troche M, Suarez E, Crombet T, Sánchez B, Casacó A, Macías A, Mazorra Z. Caballero I, et al. Among authors: casaco a. Front Pharmacol. 2017 May 10;8:263. doi: 10.3389/fphar.2017.00263. eCollection 2017. Front Pharmacol. 2017. PMID: 28539888 Free PMC article.
Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma.
Casacó A, López G, García I, Rodríguez JA, Fernández R, Figueredo J, Torres L, Perera A, Batista J, Leyva R, Peña Y, Amador Z, González A, Estupiñan B, Coca M, Hernández A, Puig M, Iglesias M, Hernández A, Ramos M, Rodríquez L, Suarez N. Casacó A, et al. Cancer Biol Ther. 2008 Mar;7(3):333-9. doi: 10.4161/cbt.7.3.5414. Epub 2007 Dec 13. Cancer Biol Ther. 2008. PMID: 18094616 Clinical Trial.
Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab.
Arteaga ME, Ledón N, Casacó A, Pardo B, García M, Boleda M, Viña L, Orphee R, Hernández O, González C, Fuentes D, Rodríguez V, Charro L, Baro F, Macías A, Pérez A, Morales Y, Subirós N, González B, Ramos M, Rodriquez L, Ballester-Labrada A, Crombet T. Arteaga ME, et al. Among authors: casaco a. Cancer Biol Ther. 2007 Sep;6(9):1390-5. doi: 10.4161/cbt.6.9.4539. Epub 2007 Jun 5. Cancer Biol Ther. 2007. PMID: 17827980
Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc.
Oliva JP, Valdés Z, Casacó A, Pimentel G, González J, Alvarez I, Osorio M, Velazco M, Figueroa M, Ortiz R, Escobar X, Orozco M, Cruz J, Franco S, Díaz M, Roque L, Carr A, Vázquez AM, Mateos C, Rubio MC, Pérez R, Fernández LE. Oliva JP, et al. Among authors: casaco a. Breast Cancer Res Treat. 2006 Mar;96(2):115-21. doi: 10.1007/s10549-005-9064-0. Epub 2005 Dec 2. Breast Cancer Res Treat. 2006. PMID: 16322892 Clinical Trial.
48 results